A5079941141- Venous Thromboembolism Diagnosis and Management
- Atrial Fibrillation Management and Outcomes
- Heparin-Induced Thrombocytopenia and Thrombosis
- Blood Coagulation and Thrombosis Mechanisms
- Platelet Disorders and Treatments
- Antiplatelet Therapy and Cardiovascular Diseases
- Acute Myocardial Infarction Research
- Systemic Lupus Erythematosus Research
- Central Venous Catheters and Hemodialysis
- Cardiac Arrhythmias and Treatments
- Vitamin K Research Studies
- Blood transfusion and management
- Blood groups and transfusion
- Hemoglobinopathies and Related Disorders
- Diagnosis and Treatment of Venous Diseases
- Acute Ischemic Stroke Management
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Case Reports on Hematomas
- Meta-analysis and systematic reviews
- Pharmacovigilance and Adverse Drug Reactions
- Sepsis Diagnosis and Treatment
- Iron Metabolism and Disorders
- Ultrasound in Clinical Applications
- Clinical practice guidelines implementation
- Myeloproliferative Neoplasms: Diagnosis and Treatment
McMaster University
2016-2025
St. Joseph's Hospital
2013-2024
St. Joseph’s Healthcare Hamilton
2014-2024
University of Calgary
2012-2024
King's College London
2024
Population Health Research Institute
2016-2024
St. Thomas Hospital
2024
St Thomas' Hospital
2024
North Bristol NHS Trust
2013-2024
Southmead Hospital
1999-2022
Bleeding is a complication of treatment with factor Xa inhibitors, but there are no specific agents for the reversal effects these drugs. Andexanet designed to reverse anticoagulant inhibitors.Healthy older volunteers were given 5 mg apixaban twice daily or 20 rivaroxaban daily. For each inhibitor, two-part randomized placebo-controlled study was conducted evaluate andexanet administered as bolus plus 2-hour infusion. The primary outcome mean percent change in anti-factor activity, which...
Many patients with the antiphospholipid antibody syndrome and recurrent thrombosis receive doses of warfarin adjusted to achieve an international normalized ratio (INR) more than 3.0. However, there are no prospective data support this approach thromboprophylaxis.We performed a randomized, double-blind trial in which antibodies previous were assigned enough INR 2.0 3.0 (moderate intensity) or 3.1 4.0 (high intensity). Our objective was show that high-intensity effective preventing...
Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for reversal inhibitors.We evaluated 352 patients who had acute major bleeding within 18 hours after administration inhibitor. The received bolus andexanet, followed by 2-hour infusion. coprimary outcomes were the percent change in anti-factor activity andexanet treatment and percentage with excellent or good hemostatic efficacy at 12 end infusion, adjudicated on basis prespecified criteria. Efficacy was...
Warfarin is very effective in preventing recurrent venous thromboembolism but also associated with a substantial risk of bleeding. After three months conventional warfarin therapy, lower dose anticoagulant medication may result less bleeding and still prevent thromboembolism.
Andexanet alfa (andexanet) is a recombinant modified human factor Xa decoy protein that has been shown to reverse the inhibition of in healthy volunteers.
Background— Acute kidney injury (AKI) after cardiac surgery is a major health issue. Lacking effective therapies, risk factor modification may offer means of preventing this complication. The objective the present study was to identify and determine prognostic importance such factors. Methods Results— Data from multicenter cohort 3500 adult patients who underwent at 7 hospitals during 2004 were analyzed (using multivariable logistic regression modeling) independent relationships between 3...
IMPORTANCE Clostridium difficile infection (CDI) is a major burden in health care and community settings.CDI recurrence of particular concern because limited treatment options associated clinical control issues.Fecal microbiota transplantation (FMT) promising, but not readily available, intervention.OBJECTIVE To determine whether frozen-and-thawed (frozen, experimental) FMT noninferior to fresh (standard) terms efficacy among patients with recurrent or refractory CDI assess the safety both...
<b>Background:</b> Whether to continue oral anticoagulant therapy beyond 6 months after an “unprovoked” venous thromboembolism is controversial. We sought determine clinical predictors identify patients who are at low risk of recurrent could safely discontinue anticoagulants. <b>Methods:</b> In a multicentre prospective cohort study, 646 participants with first, unprovoked major were enrolled over 4-year period. Of these, 600 completed mean 18-month follow-up in September 2006. collected...
The antiphospholipid syndrome (APS) is defined by the presence of thrombosis and/or pregnancy morbidity in combination with persistent circulating antibodies: lupus anticoagulant, anticardiolipin antibodies anti-β2-glycoprotein I medium to high titers. management patients APS a subject controversy. This set recommendations result an effort produce guidelines for therapy within group specialist physicians Cardiology, Neurology, Hematology, Rheumatology and Internal Medicine, clinical research...
Antiphospholipid antibodies are autoantibodies directed against proteins that bind to phospholipid. antibody syndrome (APS) refers the association between antiphospholipid and thrombosis risk or pregnancy morbidity. Patients with APS may be at increased of recurrent arterial venous loss.To systematically review evidence for treatment in patients APS.Search MEDLINE (1966 November 2005) Cochrane Library electronic databases (2005) reference lists randomized trials, meta-analyses prospective...